AlSuleimani Y M, Hiley C R
Department of Pharmacology, University of Cambridge, Cambridge, UK.
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Alkoudh, Sultanate of Oman.
Br J Pharmacol. 2015 Jun;172(12):3043-57. doi: 10.1111/bph.13107. Epub 2015 Apr 24.
Lysophosphatidylinositol (LPI), a lipid signalling molecule, activates GPR55 and elevates intracellular Ca(2+). Here, we examine the actions of LPI in the rat resistance mesenteric artery and Ca(2+) responses in endothelial cells isolated from the artery.
Vascular responses were studied using wire myographs. Single-cell fluorescence imaging was performed using a MetaFluor system. Hypotensive effects of LPI were assessed using a Biopac system.
In isolated arteries, LPI-induced vasorelaxation was concentration- and endothelium-dependent and inhibited by CID 16020046, a GPR55 antagonist. The CB1 receptor antagonist AM 251 had no effect, whereas rimonabant and O-1918 significantly potentiated LPI responses. Vasorelaxation was reduced by charybdotoxin and iberiotoxin, alone or combined. LPI decreased systemic arterial pressure. GPR55 is expressed in rat mesenteric artery. LPI caused biphasic elevations of endothelial cell intracellular Ca(2+). Pretreatment with thapsigargin or 2-aminoethoxydiphenyl borate abolished both phases. The PLC inhibitor U73122 attenuated the initial phase and enhanced the second phase, whereas the Rho-associated kinase inhibitor Y-27632 abolished the late phase but not the early phase.
LPI is an endothelium-dependent vasodilator in the rat small mesenteric artery and a hypotensive agent. The vascular response involves activation of Ca(2+)-sensitive K(+) channels and is not mediated by CB1 receptors, but unexpectedly enhanced by antagonists of the 'endothelial anandamide' receptor. In endothelial cells, LPI utilizes PLC-IP3 and perhaps ROCK-RhoA pathways to elevate intracellular Ca(2+). Overall, these findings support an endothelial site of action for LPI and suggest a possible role for GPR55 in vasculature.
溶血磷脂酰肌醇(LPI)是一种脂质信号分子,可激活GPR55并升高细胞内Ca²⁺。在此,我们研究LPI在大鼠肠系膜阻力动脉中的作用以及从该动脉分离的内皮细胞中的Ca²⁺反应。
使用线肌张力测定仪研究血管反应。使用MetaFluor系统进行单细胞荧光成像。使用Biopac系统评估LPI的降压作用。
在离体动脉中,LPI诱导的血管舒张具有浓度依赖性和内皮依赖性,并被GPR55拮抗剂CID 16020046抑制。CB1受体拮抗剂AM 251无作用,而利莫那班和O - 1918显著增强LPI反应。单独或联合使用蝎毒素和iberiotoxin可降低血管舒张作用。LPI降低全身动脉压。GPR55在大鼠肠系膜动脉中表达。LPI引起内皮细胞内Ca²⁺的双相升高。用毒胡萝卜素或2 - 氨基乙氧基二苯硼酸预处理可消除两个阶段。PLC抑制剂U73122减弱初始阶段并增强第二阶段,而Rho相关激酶抑制剂Y - 27632消除晚期阶段但不消除早期阶段。
LPI是大鼠小肠系膜动脉中的内皮依赖性血管舒张剂和降压剂。血管反应涉及Ca²⁺敏感钾通道的激活,且不是由CB1受体介导的,但出乎意料的是被“内皮花生四烯酸酰胺”受体拮抗剂增强。在内皮细胞中,LPI利用PLC - IP3途径,可能还利用ROCK - RhoA途径来升高细胞内Ca²⁺。总体而言,这些发现支持LPI在内皮的作用位点,并提示GPR55在脉管系统中可能具有作用。